Search from website
Search from website
BioBlock®, a nasal spray containing bovine antibodies against SARS-CoV-2, is produced in collaboration with Estonian scientists and entrepreneurs with the intention to prevent the spread of the virus.
The concept of colostrum-derived nasal spray is led by Professor Mart Ustav.
2. Antibodies transferred to colostrum
3. Separation of whey from colostrum
4. Antibodies are purified, pasteurized and sterilized
5. Antibody containing solution is formulated and dispensed into nasal spray bottles
Deposition of BioBlock® intranasally and orally
The antibodies form a protective layer on the mucosal epithelium
Viral particles that enter the upper respiratory tract are neutralized by the antibodies on the mucous
Spray 2 times into each nostril, 3-4 times a day, before and after visiting crowded places.
We recommend to use the spray again after blowing the nose.
BioBlock® is effective on the nasal mucosa up to 4 hours and one bottle contains 150 spray doses.
Syrian Golden Hamsters (n=8) were administered BioBlock intranasally at two different concentrations (0.1 mg/mL and 0.2 mg/mL), followed by an infection of SARS-CoV-2 virus (105 pfu). After 4 days the lung viral titer was determined. BioBlock antibody solution reduces viral load even after a single intranasal administering dose.
Eight people were administered 400 µl of BioBlock nasal spray solution. Filter paper piecer (15 µl) were placed onto the nasal mucosa and the concentration of bovine antibodies was measured.
Kangro K, Kurašin M, Gildemann K, Sankovski E, Žusinaite E, et al. (2022) Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents. PLOS ONE 17(6): e0268806. Read the paper here.
A USPTO patent application (No. 63/150.833) has been submitted by the product developers.
© 2026 Icosagen
